Results for the quarter ended 30.06.2025
Awaiting price reaction for this filing.
Sangam Health Care Products Ltd reported unaudited results for Q1 FY26 (quarter ended 30 June 2025), with net sales of Rs. 281.67 lakhs, down from Rs. 339.18 lakhs in Q1 FY25 — a YoY decline of roughly 17%. Total income for the quarter stood at Rs. 281.67 lakhs versus Rs. 260.28 lakhs in the preceding quarter (Q4 FY25). The company swung from a small loss before tax of Rs. 0.74 lakhs in Q1 FY25 to a profit before tax of Rs. 10.49 lakhs in Q1 FY26. Total expenses came in at Rs. 271.17 lakhs, including raw material costs of Rs. 166.21 lakhs and employee costs of Rs. 40.89 lakhs. The statutory auditor M M Reddy & Co. issued an unqualified limited review report, and the Board approved their reappointment for a 5-year term, subject to shareholder approval.
Mixed signals for shareholders: revenue shrank year-on-year but profitability improved, suggesting better cost control or product mix. The 31st AGM is scheduled for 30 September 2025, and the stock's book closure runs from 24–30 September 2025.